Neurogastrx
Woburn, US · Founded 2012 · 2 employees on LinkedIn · 9 known investors
Find your way into Neurogastrx
177 people in our graph share verified history with the Neurogastrx team — schools, employers, funds. One of them is your warm intro.
Mike Fitzgeraldunlockedknows Cyril De Colle · together at Roche (overlapped)
×3knows the team · via Roche
knows the team · via Jazz Pharmaceutical
knows the team · via Neurogastrx
×6knows the team · via Amgen
Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders. It focuses on science-driven drug development to address GI conditions that affect patients' quality of life.
Founders & leadership
Neurogastrx was founded in 2012 by Cyril De Colle.
CD
Cyril De ColleinFounder & Chief Scientific Officer2011–2025Cyril De Colle is founder and Chief Scientific Officer of Neurogastrx, a clinical-stage biopharmaceutical company developing therapies for gastrointestinal disorders. He brings over 25 years of experience in drug discovery and clinical development across multiple therapeutic areas, with expertise spanning target identification, preclinical pharmacology, regulatory affairs, and clinical trial management.
CD
CYRIL DE COLLEinFounder & Chief Scientific Officer2011–2025
JD
JAMES DETOREExecutive
JO
JAMES O'MARAinPresident and CEO2017–2025
PR
PAUL ROGERSinChief Commercial Officer (CCO)
Board
DA
DAVID ALLISONBoard director
KV
KLAUS VEITINGERBoard director
KK
KEVIN KOCHBoard director
AR
AARON ROYSTONBoard director
Investors · 9
5AM VenturesBoston · $100K – $4M
OrbiMedNew York · $1M – $75M
Samsara BioCapitalPalo Alto
venBio PartnersSan Francisco
Vivo CapitalPalo Alto · $10M – $50M
RTW Investments L.P.reportedNew York
venBio Global StrategicreportedSan Francisco
Westlake Village BioPartnersreportedLos Angeles · $100K – $5Mvia David Allison · board
Also in the syndicate · 1
venBio
Reported raises · per SEC filings
Form D private placements$80M disclosed across 2 rounds · 2021
▶$60MraisedJul 2021 · 10 investors · BiotechnologyRule 506(b)
▶$60MraisedJul 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- AARON ROYSTONDirector
- CYRIL DE COLLEExecutive Officer, Director
- DAVID ALLISONDirector
- KLAUS VETTINGERDirector
- JAMES DETOREExecutive Officer
- PAUL ROGERSExecutive Officer
- JAMES O'MARAExecutive Officer, Director
- KEVIN KOCHDirector
- Amount sold
- $60M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$20MraisedJul 2021 · 4 investors · BiotechnologyRule 506(b)
▶$20MraisedJul 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CYRIL DE COLLEExecutive Officer, Director
- JAMES DETOREExecutive Officer
- DAVID ALLISONDirector
- KLAUS VEITINGERDirector
- JAMES O'MARAExecutive Officer, Director
- KEVIN KOCHDirector
- AARON ROYSTONDirector
- PAUL ROGERSExecutive Officer
- Amount sold
- $20M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Neurogastrx do?
- Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders. It focuses on science-driven drug development to address GI conditions that affect patients' quality of life.
- Who founded Neurogastrx?
- Neurogastrx was founded by Cyril De Colle in 2012.
- Who are Neurogastrx's investors?
- Neurogastrx's investors include 5AM Ventures, OrbiMed, Samsara BioCapital, venBio Partners, Vivo Capital, RTW Investments L.P., venBio Global Strategic, Westlake Village BioPartners.
- How much funding has Neurogastrx raised?
- Neurogastrx has disclosed $80M raised across 2 rounds.
- Where is Neurogastrx headquartered?
- Neurogastrx is headquartered in Woburn, US.